Newsletter August 2017

Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis

Recruitment update

151 participants have been recruited into OPTIMA to date, with 17 randomised in August so far. Thank you all for your continued support of the study. **Our target is to recruit 39 participants this month.**

A special mention to **University Hospital Coventry** who have currently recruited the most participants and **Blackpool Victoria Hospital** for recruiting 4 participants in July.

Recruitment tip of the month: Exploring patient preferences

How do you respond to a patient that expresses a treatment preference about chemotherapy? Try to unpack the basis of their preference, as per the following consultant:

"I always do (explore preferences). You want to make sure they've not got some completely irrational idea about it, or they've misunderstood."

Through gently probing a patient's preference, you can check how informed they are. Patients can sometimes hold misconceptions or may have incomplete knowledge about treatments.

Patients are usually happy to discuss their views on treatments, if given an opportunity to do so.

Have you got any questions about discussing the OPTIMA study with patients?
Please contact carmel.conefrey@bristol.ac.uk

Clarification of the exclusion criteria 'Trial entry more than 8 weeks after completion of breast cancer surgery'

Trial entry is defined as the date of consent. Therefore to be eligible patients must give written informed consent within 8 weeks of completing their breast cancer surgery.

Completion of breast cancer surgery refers to the patient's final surgery for breast cancer. For example, if a patient has a wide local excision followed by an axillary clearance surgery at a later date, the patient would be eligible to give consent up to 8 weeks after the date of the axillary clearance surgery.

Please note that participants must have completed all planned surgery for breast cancer, including axillary surgery, prior to randomisation. With the exception of re-excision of margins or completion mastectomy which may be undertaken after chemotherapy.

Qualitative Recruitment Study: Audio-Recording

If you have agreed to audio-record as part of the QRS, please ask your next potential OPTIMA patient if you can record their appointment. We need your recordings to develop training and support for centres across the OPTIMA study. We will anonymise any extracts we use.

64 SITES OPEN
45 SITES RECRUITING

Please see overleaf for a list of sites that have recruited into OPTIMA

You can now email the Tissue Transit Form to the OPTIMA trial office

When sending tumour block to the OPTIMA central laboratory you enclose with the block a completed Tissue Transit Form and the relevant anonymised histology reports. We also ask you to send a copy of these documents to the trial office. Previously we have required these documents to be faxed to the trial office but we are now also able to receive these documents via email.

If you wish to email complete Tissue Transit Forms to the trial office please send the email not to the team inbox but to our individual accounts (see below). This is due to the nature of the data. Please also include an appropriate non-redistribution disclaimer in your email.

Please note: the Tissue Transit Form contains participant initials and date of birth. Please consult your organisation's policies to ensure you are permitted to transfer this data via email. We are still happy to accept Tissue Transit Forms via fax if this is your preferred method.

Please send completed Tissue Transit Forms and anonymised histology reports either:

- via fax to 02476 150549
- via email to all three following email addresses:
  a.f.campbell@warwick.ac.uk
  k.m.packard@warwick.ac.uk
  g.dotchin@warwick.ac.uk

Please don't hesitate to contact us

If you have any questions or experience any difficulties with recruitment please don't hesitate to contact us, the OPTIMA team is very willing to help.

OPTIMA trial office
Amy Campbell, Clinical Trial Coordinator
T: 02476 151948, E: optima@warwick.ac.uk

Qualitative Recruitment Study
Carmel Conefrey
T: 01179 287296, E: carmel.conefrey@bristol.ac.uk

Recruitment per site

Site *(Information correct as of 18/08/2017)*	Patients randomised
University Hospital Coventry	16
Blackpool Victoria Hospital	10
Mount Vernon Hospital	10
University Hospitals of North Midlands NHS Trust	9
Addenbrooke's Hospital	8
Luton and Dunstable University Hospital	7
NHS Lanarkshire	6
Wrexham Maelor Hospital, Wrexham	6
Bristol Haematology & Oncology Centre	5
Russells Hall Hospital, Dudley	5
Barnet Hospital	4
Macclesfield District Hospital	4
Royal Alexandra Hospital, Paisley	4
Salisbury District Hospital	4
Lister Hospital	3
Pennine Acute Hospitals	3
Peterborough City Hospital	3
Royal Free Hospital	3
Beatson West of Scotland Cancer Centre	2
Bedford Hospital	2
Birmingham City Hospital	2
Glan Clwyd Hospital, Bodelwyddan	2
Inverclyde Royal Hospital	2
New Cross Hospital, Wolverhampton	2
Nottingham University Hospital	2
Royal Devon and Exeter Hospital	2
Royal Shrewsbury Hospital	2
The Christie	2
University Hospital of North Tees	2
University Hospitals of Morecambe Bay NHS Foundation Trust	2
Western General Hospital, Edinburgh	2
Ysbyty Gwynedd, Bangor	2
Chase Farm Hospital	1
Derriford Hospital, Plymouth	1
Dumfries and Galloway Royal Infirmary	1
East Kent Hospitals NHS Foundation Trust	1
Forth Valley Hospital	1
Northumbria Healthcare NHS Foundation Trust	1
Queen Elizabeth Hospital, Gateshead	1
Queens Hospital, Burton upon Trent	1
Royal Hampshire County Hospital	1
St Margaret's Hospital, Epping	1
Sunderland Royal Hospital	1
Whittington Hospital	1
York Hospital	1